High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$47.4M
$47,398,246
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-03-02 | $490,314 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -17.1%
|
2026-03-02 | $1,049,507Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-03-02 | $27,409 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-03-02 | $60,304 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -20.0%
|
2026-02-23 | $1,491,638Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-02-23 | $84,968 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-02-04 | $47,059 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -10.4%
|
2026-02-04 | $825,853 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -20.5%
|
2026-02-03 | $265,413 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -37.2%
|
2026-02-03 | $4,659,584Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -26.0%
|
2026-02-02 | $4,317,009Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -16.2%
|
2026-02-02 | $245,896 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 Sell
2026-01-30
$821,810
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 Sell
|
2026-01-30 | $821,810 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -50.0%
2026-01-23
$805,110
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -50.0%
|
2026-01-23 | $805,110 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2026-01-20 | $147,556 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -14.3%
|
2026-01-20 | $2,590,384Large | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -33.3%
2026-01-16
$790,346
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -33.3%
|
2026-01-16 | $790,346 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -25.0%
2026-01-09
$815,634
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -25.0%
|
2026-01-09 | $815,634 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -14.3%
2025-12-19
$767,582
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -14.3%
|
2025-12-19 | $767,582 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 Sell
2025-12-18
$1,180,053Large
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 Sell
|
2025-12-18 | $1,180,053Large | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -72.1%
2025-12-17
$3,060,280Large
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -72.1%
|
2025-12-17 | $3,060,280Large | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -12.5%
2025-12-16
$766,420
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -12.5%
|
2025-12-16 | $766,420 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -11.1%
|
2025-12-15 | $2,525,322Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-12-15 | $143,850 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -50.0%
2025-12-03
$4,375,008Large
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -50.0%
|
2025-12-03 | $4,375,008Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-12-01 | $149,498 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -41.6%
2025-12-01
$727,856
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -41.6%
|
2025-12-01 | $727,856 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Urist Marshall
• Officer • EVP, Research & Investments
10b5-1 SellΔOwn -11.3%
2025-12-01
$931,633
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Research & Investments
10b5-1 SellΔOwn -11.3%
|
2025-12-01 | $931,633 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 SellΔOwn -10.0%
|
2025-12-01 | $2,624,459Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-24 | $23,687 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-24 | $120,882 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-24 | $405,645 | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-24 | $2,132,292Large | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -92.3%
2025-11-19
$106,052
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -92.3%
|
2025-11-19 | $106,052 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 Sell
2025-11-19
$8,978
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 Sell
|
2025-11-19 | $8,978 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 Sell
2025-11-19
$96,347
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 Sell
|
2025-11-19 | $96,347 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -91.2%
2025-11-19
$977,260
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -91.2%
|
2025-11-19 | $977,260 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 Sell
2025-11-19
$179,394
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 Sell
|
2025-11-19 | $179,394 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -91.2%
2025-11-19
$1,814,449Large
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -91.2%
|
2025-11-19 | $1,814,449Large | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -43.2%
2025-11-19
$180,528
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -43.2%
|
2025-11-19 | $180,528 | S | Form 4 |
|
RPRX
S
Royalty Pharma plc
Lloyd George W.
• Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -81.7%
2025-11-19
$1,829,650Large
|
||||||
| RPRX |
Royalty Pharma plc
|
Officer • EVP, Investments & CLO
10b5-1 SellΔOwn -81.7%
|
2025-11-19 | $1,829,650Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-17 | $2,587,939Large | S | Form 4 |
| RPRX |
Royalty Pharma plc
|
CFO
10b5-1 Sell
|
2025-11-17 | $147,390 | S | Form 4 |